Working with dengue virus in the BSL-3 lab of Heidelberg University. Also shown in this photomontage are fluorescent images of genetically engineered cells that contain the protease reporter constructs. In addition, the chemical structure of an antiviral compound and its effect on the replication of dengue virus is shown. | © Research Group Medicinal Chemistry, Institute of Pharmacy and Molecular Biotechnology (IPMB), Heidelberg University
Working with dengue virus in the BSL-3 lab of Heidelberg University. Also shown in this photomontage are fluorescent images of genetically engineered cells that contain the protease reporter constructs. In addition, the chemical structure of an antiviral compound and its effect on the replication of dengue virus is shown. Research Group Medicinal Chemistry, Institute of Pharmacy and Molecular Biotechnology (IPMB), Heidelberg University - Heidelberg research group seeks and develops inhibitors against flaviand coronaviruses New drugs are intended to help stop viral zoonoses - infections that jump from animals to humans. To study suitable inhibitors, Christian Klein from the Institute of Pharmacy and Molecular Biotechnology (IPMB) of Heidelberg University is receiving funding in the amount of 450,000 euros from the Volkswagen Foundation. The project is focussed on flaviand coronaviruses, which cause infectious diseases such as Zika, dengue, West Nile Fever, and Middle East Respiratory Syndrome (MERS). The goal is to identify drugs to fight these pathogens and perform preclinical studies.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
Your Benefits
- Access to all content
- Receive newsmails for news and jobs
- Post ads
